Inhibrx Biosciences Azioni (NASDAQ: INBX)

Ultime notizie per Inhibrx Biosciences (NASDAQ:INBX) Azioni

Inhibrx Biosciences

Inhibrx

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Inhibrx Biosciences Inc

Inhibrx Inc COM

Oppenheimer analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Outperform and raises the price target from $121 to $135.

News

Price Target

Analyst Ratings

EEFT

Oppenheimer Maintains Outperform on Euronet Worldwide, Raises Price Target to $135

RBC Capital analyst Frank Morgan maintains eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) with a Sector Perform and lowers the price target from $13 to $11.

EHTH

RBC Capital Maintains Sector Perform on eHealth, Lowers Price Target to $11

Oppenheimer analyst Martin Yang maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $260 to $480.

Oppenheimer Maintains Outperform on AppLovin, Raises Price Target to $480

Oppenheimer analyst Owen Lau maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Outperform and raises the price target from $265 to $358.

COIN

Oppenheimer Maintains Outperform on Coinbase Glb, Raises Price Target to $358

RBC Capital analyst Scott Hanold maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Sector Perform and raises the price target from $35 to $40.

RBC Capital Maintains Sector Perform on Range Resources, Raises Price Target to $40

Oppenheimer analyst Rupesh Parikh reiterates Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and maintains $165 price target.

Reiteration

Oppenheimer Reiterates Outperform on Target, Maintains $165 Price Target

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and the U.S. Department of Justice are set to present closing arguments on Monday in a trial to determine if Google&#8217;s advertising technology<a href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst"> constitutes an illegal monopoly.</a>
The Details: The DOJ alleges Google maintains a monopoly in "open-web display advertising" by dominating all aspects of the marketplace with a funnel of technologies that match online publishers to advertisers as well as controls the ad exchange market, which matches the buy side to the sell side.&nbsp;
"One monopoly is bad enough. But a trifecta of monopolies is what we have here," Justice Department lawyer Julia Tarver Wood said during her opening statement.
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Google says that the DOJ's case is focused on a narrow niche of digital advertising and that the company's market share of 25% has been decreasing as competition has increased in the space.&nbsp;
According to the AP, court documents show that Google argues the government's case "boil(s) down to the persistent complaints of a handful of Google's rivals and several mammoth publishers."
The case is being heard by U.S. District Judge Leonie Brinkema, in Alexandria, Virginia, who is expected to decide the case and issue a written ruling by the end of the year.&nbsp;
What Else: A District of Columbia judge, in a separate case, ruled in August that Google's search engine business does constitute a monopoly. The DOJ presented its proposed remedies last week, which included the requirement for Alphabet to divest Google Chrome, the internet&#8217;s leading browser with over 60% market share globally.
Other <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale#google_vignette">proposals included</a> forcing Google to share search data with competitors, and ending default search agreements, which make Google the automatic search engine on devices and web browsers like Apple&#8217;s Safari.
&#8220;Google&#8217;s unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways,&#8221; the DOJ said in a statement.
The judge is expected to deliver a final decision in that case next summer.&nbsp;
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alphabet shares are up 1.92% at $167.92 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a></li>
</ul>
Image: Shutterstock

Large Cap

Legal

Movers

Tech

GOOG

GOOGL

Google, DOJ Present Closing Arguments In AdTech Trial Monday

RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Outperform and lowers the price target from $25 to $16.

CATX

RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $16

WIIM

RNAZ

TransCode Therapeutics shares are trading lower after the company announced a 1-for-33 reverse stock split.

Wells Fargo analyst Roger Read maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $42 to $52.

Wells Fargo Maintains Overweight on EQT, Raises Price Target to $52

Analog Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NYSE">ADI</a>) short percent of float has fallen 21.05% since its last report. The company recently reported that it has 7.43 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Analog Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Analog Devices has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Analog Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Analog Devices's peer group average for short interest as a percentage of float is 4.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Analog Devices's Recent Short Interest

Old National's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NYSE">ONB</a>) short percent of float has risen 7.32% since its last report. The company recently reported that it has 9.46 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Old National Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Old National has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Old National's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Old National's peer group average for short interest as a percentage of float is 3.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Old National's Recent Short Interest

Time's running out. The Biden administration is in a mad dash to finalize billions in CHIPS Act deals before Trump takes office. With $39 billion in funding at stake, there's no room for delays.
The CHIPS Act, signed in 2022, was supposed to bring <a href="https://www.benzinga.com/markets/equities/24/10/41387939/chipmakers-rally-nvidia-smashes-records-on-tsmc-blowout-earnings-gold-hit-all-time-highs-whats-d">chip production</a> home. The goal? Secure supply chains and cut reliance on Taiwan for advanced semiconductors. It's a big deal for U.S. manufacturing. But there's a catch. While 90% of the money is allocated, most of it hasn't been locked down yet. Only two deals, worth $6.6 billion, are fully finalized, <a href="https://www.commerce.gov/news/press-releases/2024/11/biden-harris-administration-announces-chips-incentives-award-tsmc">according to the Commerce Department.</a>
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Commerce Secretary Gina Raimondo promised to allocate every dollar by the end of the year. But progress? It's been slow. And patience is wearing thin. "We are disappointed by how long and how slow the dispensing of funds has been," said Intel CEO Pat Gelsinger, as reported by Bloomberg. He's frustrated. The process has dragged on for over two years.
President Joe Biden's team is trying to speed things up. Last week, they announced<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> a $6.6 billion deal </a>with Taiwan's TSMC. At least $1 billion should roll out before the year ends. But there's still a lot left to sort out. Intel, the biggest potential recipient, is still negotiating terms to unlock its share.
President-elect Donald Trump, meanwhile, isn't a fan of the CHIPS Act. He's been vocal. He thinks tariffs are a better way to push companies to make chips here. On a podcast with Joe Rogan, he called tariffs the smarter move. His team might shift gears when he takes office. But here's the thing: once a CHIPS Act deal is finalized, it's tough to undo. They're legally binding unless companies don't hold up their end of the bargain.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Analysts like Jeff Koch say Trump could slow things down, even if he doesn't scrap the CHIPS Act. "This had the ancillary benefit of pushing the Biden administration to cut through red tape and disburse CHIPS Act funds while still in power," Koch told Business Insider.
There's also pressure from the clock. January is fast approaching. Biden's team knows the window to finalize these agreements is closing. The next administration could stall or rewrite the rules, adding more uncertainty to a complicated process.
And it's not just about securing funding. There are benchmarks. <a href="https://www.benzinga.com/news/earnings/24/10/41654832/intel-likely-to-report-q3-loss-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Companies like Intel </a>need clear terms to access the money. Another layer of bureaucracy is slowing things down. For Biden, it's a race against time to solidify the vision of the CHIPS Act before Trump's team takes over.
The stakes are high. America needs these funds locked in to compete globally. Chips power everything from smartphones to cars, so falling behind isn't an option. All eyes are on whether Biden can pull this off in time. The pressure's on and there's no room for missteps.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Startups

'We Are Disappointed.' Intel CEO Criticizes Delays As Biden Pushes $6.6 Billion To TSMC

Zebra Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NYSE">ZBRA</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 511 thousand shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zebra Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zebra Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zebra Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zebra Technologies's peer group average for short interest as a percentage of float is 6.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ZBRA

Looking Into Zebra Technologies's Recent Short Interest

Diana Shipping shares are trading lower after the company reported worse-than-expected Q3 sales results.

IMUX

Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.

Wells Fargo maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Equal-Weight and raises the price target from $83 to $100.

Wells Fargo Maintains Equal-Weight on Expand Energy, Raises Price Target to $100

Palatin Technologies shares are trading higher after the company announced the completion of enrollment in its Phase 2 Study of PL8177.

Editor's Note: The headline has been corrected to accurately reflect the quoted material.
Elon Musk on Saturday shared a cryptic tweet on X, hinting at a significant turning point in human history.
What Happened: Musk&nbsp;responded to a post on X by Bojan Tunguz, which referred to an unspecified event as &#8220;one of the major inflection&nbsp;points of human history.&#8221; Musk&#8217;s reply was enigmatic, stating, &#8220;I knew if I brought&nbsp;a sink they would have&nbsp;to let that sink in.&nbsp;How could they not?&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I knew if I brought a sink they would have to let that sink in. How could they not? <a href="https://t.co/voEVBMC7Ht">https://t.co/voEVBMC7Ht</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860199022121943545?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Tesla and SpaceX CEO&#8217;s post on X has left his followers intrigued, as they attempt to decipher the meaning behind his cryptic words.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a>
Why It Matters: Musk is known for his cryptic tweets, which often lead to widespread speculation. His recent tweet, which suggests a significant turning point in human history, has sparked a flurry of theories among his followers.
While the exact meaning behind Musk&#8217;s tweet remains unclear, it underscores his reputation as a thought leader in the tech industry, known for pushing boundaries and challenging conventional thinking.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42152586/judge-rejects-sec-bid-to-penalize-musk-over-missed-deposition">Judge Rejects SEC Bid to Penalize Musk Over Missed Deposition</a></li>
</ul>
Photo: Shutterstock

Social Media

'I Knew If I Brought A Sink': What Does Elon Musk's Cryptic Tweet Mean? (CORRECTED)

B of A Securities analyst Omar Dessouky maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $252 to $375.

B of A Securities Maintains Buy on AppLovin, Raises Price Target to $375

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibrx (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbx-stock-quote/">INBX</a>) just reported results for the first quarter of 2024.<ul><li>Inhibrx reported earnings per share of -$1.44. This was above the analyst estimate for EPS of -$1.51.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/inbx-stock-earnings-inhibrx-for-q1-of-2024/">INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024

Inhibrx Biosciences (INBX) is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma (IMAB) in the United ...

Inhibrx prevails in trade secret case with I-Mab

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibrx (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbx-stock-quote/">INBX</a>) just reported results for the first quarter of 2024.<ul><li>Inhibrx reported earnings per share of -$1.44. This was above the analyst estimate for EPS of -$1.51.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/inbx-stock-earnings-inhibrx-for-q1-of-2024/">INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Inhibrx Biosciences GAAP EPS of -$2.84

JMP Securities analyst Reni Benjamin maintained a Hold rating on Inhibrx Biosciences Inc (INBX – Research Report) today. The company's shares close...

JMP Securities Sticks to Their Hold Rating for Inhibrx Biosciences Inc (INBX)

AAPL

ACHC

ADBE

ADPT

AMZN

AVGO

BBIO

BMRN

DASH

DDOG

DLTR

EWTX

FDMT

FERG

IMAB

INBX

LBPH

MSFT

NAMS

NFLX

ORIC

PEPG

PHVS

ROIV

RPRX

TMUS

TRVI

TTWO

VKTX

WDAY

Press Releases

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, HAYN, EVBG, KAMN

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Earnings

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Comments

Inhibrx Biosciences

Notizie

Ultime notizie per Inhibrx Biosciences (NASDAQ:INBX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO